荃信生物-B涨超11% QX030N此前达成国际授权合作 赛乐信今年销售额预计达3亿元

智通财经
Jun 05

荃信生物-b(02509)涨超11%,截至发稿,涨11.09%,报13.82港元,成交额296.02万港元。消息面上,今年4月,荃信生物宣布与Caldera Therapeutics就荃信生物自主研发的临床前阶段长效自免双抗QX030N签订授权许可协议,授予Caldera开发及商业化QX030N的全球独家许可。根据协议,Caldera获授予研究、开发、注册、生产及商业化QX030N的全球独家权益。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10